202 related articles for article (PubMed ID: 1719641)
1. The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma.
Figlin RA; Abi-Aad AS; Belldegrun A; deKernion JB
Semin Oncol; 1991 Oct; 18(5 Suppl 7):102-7. PubMed ID: 1719641
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
[TBL] [Abstract][Full Text] [Related]
3. Interferons and interleukins in metastatic renal cell carcinoma.
Choudhury M; Efros M; Mittelman A
Urology; 1993 Jan; 41(1 Suppl):67-72. PubMed ID: 7678365
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
Lopez Hänninen E; Kirchner H; Atzpodien J
J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
[TBL] [Abstract][Full Text] [Related]
6. [The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer].
Wirth M
Urologe A; 1991 Mar; 30(2):77-80. PubMed ID: 1711729
[TBL] [Abstract][Full Text] [Related]
7. The current use of interferons, interleukin-2 and tumor necrosis factor in renal cell cancer.
Wirth M
Urol Int; 1991; 47(4):219-30. PubMed ID: 1723554
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic options in renal cell carcinoma.
Buzaid AC; Todd MB
Semin Oncol; 1989 Feb; 16(1 Suppl 1):12-9. PubMed ID: 2465574
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy of metastatic renal cell cancer].
Manseck A; Wirth M
Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
12. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
13. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
14. Interferon therapy for renal cell carcinoma.
Muss HB
Semin Oncol; 1987 Jun; 14(2 Suppl 2):36-42. PubMed ID: 3589703
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
16. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for metastatic renal cell carcinoma.
Wirth MP
Urol Clin North Am; 1993 May; 20(2):283-95. PubMed ID: 7684167
[TBL] [Abstract][Full Text] [Related]
18. Biologic response modifiers in the therapy of metastatic renal cell carcinoma.
Quesada JR
Semin Oncol; 1988 Aug; 15(4):396-407. PubMed ID: 2457256
[No Abstract] [Full Text] [Related]
19. Use of biological response modifiers for management of renal cell carcinoma.
Wilkinson M; Aronson F
Urol Int; 1991; 46(3):304-8. PubMed ID: 1926644
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2000; (3):CD001425. PubMed ID: 10908496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]